Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab + Intensive Chemo in AML/MDS
NCT05829434Phase 2Withdrawn
- Start
- Mar 2024
- Primary completion
- Aug 2028
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
01
Overview
A Phase 2 trial of magrolimab in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS). Planned start Mar 2024; status: withdrawn.
02
Drugs
magrolimab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05829434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05829434.